Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Suzanne Schwartz.

Executive Summary

The US FDA issued a new guidance on 8 April that outlines a comprehensive approach device manufacturers can take to address cybersecurity concerns throughout the total product life cycle of their products. See what Suzanne Schwartz, director of the agency’s Office of Strategic Partnerships and Technology Innovation, said about it here.

“Right now it's really key to have manufacturers understand the aspect of free markets that extends well beyond the device becoming authorized to go on the market.” – Suzanne Schwartz, director, US FDA Office of Strategic Partnerships and Technology Innovation

Click here for a free trial of Medtech Insight

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts